FDA Approves Merck ’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

Dateline City:
KENILWORTH, N.J. Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab VedotinKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA®(pembrolizumab), the company ’s anti-PD-1
(programmed death receptor-1) therapy, for the treatment of adult and
pediatric patients with refractory classical Hodgkin lymphoma (cHL), or
who have relapsed after three or more prior lines of therapy.Language:
EnglishContact: MerckMedia:Pamela Eisele, [phone]orKim Hamilton, [phone]orInvestor:Teri Loxam, (908) 740-1986orAmy Klug, [phone]Ticker Slug:Ticker:MRKExchange:NYSE
@Merckread more

Source: Merck.com - Corporate News - March 14, 2017 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news